Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.

Abstract

The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Adult
  • Age Factors
  • Animals
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Cell Line
  • Chlorocebus aethiops
  • Female
  • HIV Antigens / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV-1 / immunology*
  • Humans
  • Immunity, Cellular
  • Immunization, Secondary
  • Male
  • Middle Aged
  • Neutralization Tests
  • Vaccines, DNA / immunology
  • Vaccines, Synthetic / immunology
  • Vaccinia virus / immunology*
  • Young Adult

Substances

  • AIDS Vaccines
  • Antibodies, Viral
  • HIV Antigens
  • Vaccines, DNA
  • Vaccines, Synthetic